The U.S. Food and Drug Administration (FDA) has announced the first participants in its PreCheck Pilot Program, an initiative designed to accelerate the review of new pharmaceutical manufacturing facilities in the United States. The program is intended to improve supply chain resilience by allowing earlier engagement between the FDA and manufacturers during facility design and construction.
Seven companies were selected for the first phase of the program:
- Eli Lilly
- Regeneron
- Amneal Pharmaceuticals
- Cellares
- Fujifilm Biotechnologies
- Kriya Therapeutics
- Kyowa Kirin
Why This Matters for Pharma Professionals
Earlier regulatory engagement can help companies prepare manufacturing and quality systems before facilities become operational. As companies continue investing in U.S. manufacturing, this may support additional hiring across engineering, quality, manufacturing, validation, regulatory affairs, and supply chain functions over time. Hiring needs will still depend on each company’s expansion plans and business priorities.
Potential roles include:
- Manufacturing Engineer
- Validation Engineer
- QA Specialist
- QC Analyst
- Regulatory Affairs Associate
- Process Engineer
- Automation Engineer
- Supply Chain Specialist
Eli Lilly’s Continued Manufacturing Expansion
Eli Lilly has announced multiple large manufacturing investments in recent years, including additional spending in Indiana to support production capacity for current and future medicines. These investments are part of a broader strategy to expand U.S. manufacturing.
How the FDA PreCheck Program Works
The pilot program has two main phases:
- Early communication with the FDA during facility design and construction.
- Pre-application meetings and regulatory feedback to streamline manufacturing and quality processes before formal review.
Skills That Could Be Valuable
Professionals interested in manufacturing-related roles may benefit from knowledge of:
- GMP
- Validation
- Process Engineering
- Quality Systems
- Regulatory Compliance
- Pharmaceutical Manufacturing
- Automation
- Data Analysis
Final Thoughts
The FDA’s PreCheck Pilot Program reflects an ongoing effort to strengthen domestic pharmaceutical manufacturing and improve regulatory efficiency. While the program itself does not guarantee new jobs, continued investment by participating companies may create additional career opportunities as facilities are developed and expanded.
FAQ
Does the FDA PreCheck Program guarantee hiring?
No. The program is designed to streamline regulatory review of manufacturing facilities. Hiring decisions remain with each participating company.
Which companies were selected?
Eli Lilly, Regeneron, Amneal Pharmaceuticals, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin.
Why is this important?
Earlier regulatory collaboration may help companies bring manufacturing capacity online more efficiently and strengthen the U.S. pharmaceutical supply chain.
Link this article to:
- PI Industries Walk-in Drive 2026 | Research Scientist Jobs in Udaipur (12 july)
- Vamsi Pharma Walk-In Interview 2026 | Production, QA, QC & Multiple Pharma Jobs
- Top 25 Highest-Paying Pharmaceutical Companies in the USA (2026 Salary Report)
- Nagindas Hiralal Bhayani Pharma Jobs 2026 | QA, QC, Maintenance & API Openings in Ankleshwar
- Ortiv-Q3 Hiring Business Development Executive/Manager in Ahmedabad | Pharma CRO Jobs 2026
Official Sources
|
|
|
|